Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

rantee that a registrational submission will be made to the FDA based on the data described in this press release or if such registrational submission is made, that it would receive FDA approval. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol- Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

    (1) Robb AS, Forbes RA, Marcus RN, Carson Jr. WH. Efficacy of aripiprazole

    in the treatment of adolescents with schizophrenia. Poster presentation

    NR742 at: annual meeting of the American Psychiatric Association, San

    Diego, California, Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST -

    Poster Session 7.


    (2) Findling RL, Nyilas M, Auby P, Mallikaarjun S, McQuade RD, Marcus RN,

    Carson Jr. WH. Tolerability of aripiprazole in the treatment of

    adolescents with schizophrenia. Poster presentation NR741 at: annual

    meeting of the American Psychiatric Association, San Diego, California,

    Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST - Poster Session 7.


    (3) IMS Auditrac NGPS: Abilify total monthly retail prescriptions: Data

    accessed 11/2006.

CONTACT: Debra Kaufmann of Otsuka America Pharmaceutical, Inc.,+1-240-683-3568, ; or Hideki Shirai of OtsukaPharmaceutical Co., Ltd., +81-3-3292-0021, ; or David M.Rosen, Communications, +1-609-252-5675, Pager, +1-866-308-4484,, or John Elicker, Investor Relations,+1-212-546-3775, , both of Bristol-Myers Squibb Company debra.kaufmann@otsuka.com




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
(Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded ... the earnings conference call for the third quarter of ... be held at 9:00 a.m. ET on Tuesday, May ...
... 2012 First Quarter Total Revenue $856 million, including $66 million ... forma organic growth for the combined company, adjusting for the impact ... 2012 First Quarter GAAP EPS Loss of $0.04; Cash EPS ... was $0.99 , 2012 First Quarter GAAP Cash ...
Cached Medicine Technology:TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 3Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 4Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 5Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 6Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 7Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 8Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 9Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 10Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 11Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 12Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 13Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 14Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 15Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 16
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... an effort to further promote visibility and adoption of the ... made AMA journals available via its subscription services, EBSCO will ... , Long known as both a subscription agency ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... as a normal part of aging. It shouldn,t be. ... a nursing,home, and death. Suicide risk also increases with ... rate in the United States. Depression in the,elderly can ... can be challenging not to mistake them for symptoms ...
... Poster Presented at Annual Meeting of the American Academy of ... ... 11 NeoStrata today released new,clinical research that validates the benefits ... as a complement to,medical anti-aging treatments such as lasers and microdermabrasion. ...
... the UC Davis M.I.N.D. Institute and Center for Childrens ... of mothers of children with autism bind to fetal ... authors also found that the reaction was most common ... autism, which occurs when a period of typical development ...
... Spa is pleased,to announce the appointment of fitness ... "Jeanine brings outstanding credentials to Deerfield,s fitness,program," ... enable her,to fine tune our offerings so guests ... at the spa, but also learn skills to ...
... Only Non-Alcohol Product that can be ... Sprayed Directly into the Face, UNION, ... revolutionary new product for use after a,potential pathogenic exposure, MyClyns(TM), is ... site, added a customer,service center and deployed regional product specialists to ...
... Patent Expands Geographic Coverage, IRVING, ... (OTC Bulletin Board: CARN) today announced ... patent application No. 200600484, titled,"Delivery of ... Anionic,Polysaccharides," relating to the Company,s proprietary ...
Cached Medicine News:Health News:Depression in the Elderly is Complicated but Treatable, From the Harvard Mental Health Letter 2Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 3Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 4Health News:Deerfield Spa Appoints New Fitness Director 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 3Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 3
... Defibrillator was designed to be as easy ... and shares many of its features, including ... Philips HeartStart Home Defibrillator is an automated ... home use by untrained users. Although small ...
... imaging and an extraordinary combination of ... choice for the multi-specialty clinical environment. ... SSD-4000s software and hardware allows you ... exams while achieving high-quality results., ,The ...
... is a cost-effective, office-based ultrasound system. It ... quality of our more expensive ProSound models ... maneuvering in small exam rooms., ,The SSD-3500 ... data management system (iDMS) enables easy storage ...
Inquire...
Medicine Products: